OPEN END TURBO OPTIONSSCHEIN SHORT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 11:56:35 29/05/2024 pm IST | ||
| 1.343 EUR | +1.59% |
|
| 1 month | +40.63% | ||
| 3 months | +209.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 1.343 | +1.59% |
| 28/24/28 | 1.322 | +7.31% |
| 27/24/27 | 1.232 | -1.36% |
| 24/24/24 | 1.249 | +2.13% |
Real-time BOERSE MUENCHEN
Last update May 29, 2024 at 11:56 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GG09LV |
| ISIN | DE000GG09LV3 |
| Date issued | 27/11/2023 |
| Strike | 54.89 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.373 € |
|---|---|
| Lowest since issue | 0.084 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat
